(Updates Johnson & Johnson filing EUA application) Feb 5 (Reuters) - Johnson & Johnson has asked U.S. health regulators to authorize its single-dose COVID-19 vaccine for emergency use and said it will apply to European authorities in coming weeks. The U.S. FDA will hold a meeting of its Vaccines and Related Biological Products Advisory Committee on Feb. 26 to discuss the drugmaker's request. The following table gives the state of play of the main vaccine candidates. COMPANY STAGE OF DEVELOPMENT EXPECTED DOSES Pfizer Inc and New Zealand was the latest to (Nine countries for over 600 mln BioNTech SE authorize the vaccine, with a doses) total of 15 countries and the EU having authorized it. South Korea U.S. - 200 mln+ option for 400 has also approved its import. mln more UK - 40 mln; Expects to have 10 mln doses by end of 2020 EU - 600 mln Canada - 40 mln Japan - 120 mln Colombia - 1.7 mln in Feb South Korea - 20 mln Iraq - 1.5 mln Chile - 10 mln Malaysia - 12.8 mln African Union - unspecified (via COVAX) Moderna Inc Distribution under way in Canada, U.S. - 200 mln, in talks for the United States and EU. Delays additional 100 mln in delivery to Italy, France and Switzerland. Plans to test new EU - 160 mln booster shot aimed at the South African variant. UK - 17 mln Japan - 50 mln or more, to be distributed by Takeda Switzerland - 7.5 mln Canada- 40 mln Israel - 6 mln, expects to begin receiving the vaccines by March "at the latest" Singapore - Not specified Qatar- Not specified South Korea - 20 mln The Philippines - 20 mln Johnson & Johnson Applied to the U.S. FDA for U.S. - 100 mln + 200 mln more authorization of its single-dose under subsequent agreement COVID-19 vaccine for emergency use; to apply to European UK - 30 mln + option for up to 22 authorities in coming weeks mln more EU - 200 mln + 200 mln additional Canada - Up to 38 mln Japan - Not Applicable South Korea - 4 mln African Union - unspecified (via COVAX) AstraZeneca & Oxford Vaccine approved for emergency (More than 15 countries and University use by European Medicines Agency groups for over 3 bln doses) and the UK. India, Pakistan, the Philippines, South Africa, Chile U.S. - 300 mln and Brazil have also approved the shot. Deliveries to EU slowed UK - 100 mln down. EU - At least 300 mln + 100 mln additional Italy, Germany, the Netherlands and France - 300 mln + 100 mln additional Canada - Up to 20 mln Japan - 120 mln Bangladesh - 30 mln (through India's Serum Institute) Colombia - 10 mln South Korea - 20 mln The Philippines - 2.6 mln Malaysia - 6.4 mln India - 11 mln (through Serum Institute) African Union - unspecified (via COVAX) plus another 400 million doses secured Sinovac Biotech Ltd Turkey and China have granted Indonesia - 125 mln with 1.2 mln emergency use authorization for doses already secured the vaccine. Brazil - in talks for 100 mln doses Turkey - 50 mln doses (3 mln received) The Philippines to finalize negotiations for 25 mln doses Malaysia - 14 mln Chile - 60 mln doses (first shipment of nearly 2 mln received ) Gamaleya Research Institute Filed for registration in Europe; Supply deals with over 13 Russia to conduct trial of a countries including India, one-dose version; 1.5 mln have Brazil, Algeria, Bolivia and been inoculated in Russia since Argentina for at least 280 mln December. Roll out under way in doses. Belarus and Argentina. Mexico - in talks for 24 mln doses CanSino Biologics Inc Approved for use in Chinese Mexico - 10 mln-35 mln doses military. Late-stage trial under way in Pakistan and Mexico. China National Pharmaceutical China and Hungary approved the Expects to produce more than 1 Group Corp (Sinopharm) shot developed by an affiliate of bln doses in 2021 Sinopharm. Its efficacy was pegged at 79.34% by the Pakistan to purchase 1.2 million company. doses The vaccine has been used on Peru - 38 mln about 1 mln people in China in an emergency program. Bharat Biotech Vaccine granted emergency use In talks with at least 10 authorization in India with countries in South America, Asia roll-out under way and Eastern Europe Novavax Inc Europe has begun rolling review, U.S. - 100 mln Company has applied to Canada for review. Prelim data from UK - 60 mln late-stage UK trial shows vaccine is 89.3% effective in preventing Canada - Up to 76 mln COVID-19 and equally effective against UK variant; Late-stage Japan - 250 mln study under way in the U.S. and Mexico. Australia - 51 mln + option for additional 10 mln; initial doses expected by mid-2021 The Philippines - 30 mln by July 2021 Indonesia - 30 mln New Zealand - 10.7 mln EU - In negotiations Medicago Begins mid-to-late stage studies No supply deals yet of its experimental vaccine in combination with a booster from GlaxoSmithKline . Anhui Zhifei Longcom Begins Phase III trials, planning No supply deals yet Biopharmaceutical to recruit 29,000 volunteers across the world (bit.ly/3mc5WUI) (Reporting by Amruta Khandekar, Dania Nadeem, Mrinalika Roy, Vishwadha Chander, Manas Mishra, Trisha Roy, Muvija M and Pushkala Aripaka in Bengaluru; Editing by Anil D'Silva and Arun Koyyur)
我们的标准: 汤森路透“信任原则”